Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaBusiness Wire • 12 days ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Share to Feed
Prothena Co. plc (NASDAQ:PRTA Get Free Report) shares traded down 2.3% during mid-day trading on Thursday . The company traded as low as $24.53 and last traded at $24.57. 14,520 shares were...
This price move could be a signal that PRTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...
This is a Bearish indicator signaling PRTA's price could decline from here. Traders may explore shorting the stock or put options...
This price move could be a signal that PRTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...
Prothena Co. plc (NASDAQ:PRTA Free Report) Zacks Research issued their FY2026 EPS estimates for shares of Prothena in a report issued on Thursday, March 7th. Zacks Research analyst...
This indicator may be signaling that PRTA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Prothena Co. plc (NASDAQ:PRTA Get Free Report) has been assigned a consensus recommendation of Moderate Buy from the nine research firms that are covering the firm...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
This price move could be a signal that PRTA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...